<DOC>
	<DOCNO>NCT02268630</DOCNO>
	<brief_summary>This prospective observational follow-up study design ass long-term outcome Venous thromboembolism ( VTE ) assess effect new oral anticoagulant ( NOAC ) rivaroxaban prevalence post-thrombotic syndrome ( PTS ) . The study test formal hypothesis .</brief_summary>
	<brief_title>Long Term Outcomes Venous Thromboembolism</brief_title>
	<detailed_description>This prospective observational follow-up study design ass long-term outcome VTE ass effect NOAC ( rivaroxaban ) prevalence PTS . All patient diagnose treated VTE SÃ˜F 01.01.2011 invite participate study . Newly diagnose patient recruit followed-up accord study schedule base state art international guideline . First follow-up performed end treatment period , usually 3 6 month event VTE , one year patient put permanent AC . Thereafter , patient followed-up annually least 5 year end study , i.e 10 year . The primary endpoint study development PTS CTEPH VTE . There 3 visit : 3 6 month depend duration AC , 2 5 year , addition visit TTE 6 month . Remaining follow-ups perform phone mail . All patient PE examine TTE 6 month diagnosis PE . Those sign PAH refer work-up establish presence absence CTEPH specialize centre . Patients DVT evaluate PTS 2 5 year CTEPH develop dyspnoea . As part b primary objective , study allow inclusion patient previous DVT diagnose 01.01.11 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Postthrombotic Syndrome</mesh_term>
	<mesh_term>Postphlebitic Syndrome</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients objectively verify first time DVT diagnose 01.01.11 study A , OR objectively verify DVT and/or PE dignosed 01.04.14 study B . 18 year age Signed inform write consent Patients refuse consent Patients treat anticoagulant thoose include study Patients participate due logistic reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Post-thrombotic syndrome</keyword>
	<keyword>Chronic thromboembolic pulmonary hypertension</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Rivaroxaban</keyword>
</DOC>